

Profiles
December 10, 2915

Curriculum Vitae

NINA R. SCHOOLER, Ph. D.

ADDRESS: Home: 1731 34th Street NW
Washington DC 20007

Office: Department of Psychiatry and Behavioral Sciences
450 Clarkson Avenue, MSC 1203
Brooklyn NY 11203-2098

TELEPHONE: Home: (202) 338-5591
Office: (718) 221 -6104
FAX (718) 270-3030

E:MAIL ADDRESS Office: nina.schooler@gmail.com
Cell 917 543 2740

DATE OF BIRTH & PLACE: July 26, 1934, New York, NY
CITIZENSHIP: United States

EDUCATION:
1951-1955 City College of NY
B.S.S., Anthropology

POST-GRADUATE TRAINING:
1956-1969 Columbia University
Ph.D., Social Psychology

PROFESSIONAL EMPLOYMENT AND HOSPITAL APPOINTMENTS:

1963 - 1967 Research Social Psychologist
Clinical Studies Section
Psychopharmacology Service Center
National Institute of Mental Health
Chevy Chase, Maryland

1968 Professional Services Contractor
National Institute of Mental Health
Chevy Chase, Maryland

1968 - 1980

Research Psychologist
Psychopharmacology Research Branch
National Institute of Mental Health
Rockville, Maryland

1980 - 1984

Chief, Schizophrenic Disorders Section and Assistant Chief
Pharmacologic and Somatic Treatments, Research Branch
National Institute of Mental Health
Rockville, Maryland

1985 Acting Chief
Pharmacologic and Somatic Treatments Research Branch
National Institute of Mental Health
Rockville, Maryland

1985 - 1988 Assistant Chief
Schizophrenia Research Branch
National Institute of Mental Health
Rockville, Maryland

1989 - 1997 Director of Research
Special Studies Center
Mayview State Hospital
Commonwealth of Pennsylvania

1997 – 2003 Director of Psychiatry Research
The Zucker Hillside Hospital
Division of North Shore - Long Island Jewish Health System
Glen Oaks, New York

2001-2003 Senior Investigator,
North Shore-Long Island Jewish Research Institute
Division of North Shore-Long Island Jewish Health System
Glen Oaks, New York

2003 – Present Senior Research Scientist
The Zucker Hillside Hospital
Feinstein Institute for Medical Research

2004 – 2014 Senior Research Psychologist & Director MIRECC/DC
Capitol Area VISN 5 MIRECC
Washington DC VA Medical Center
Washington, DC.

ACADEMIC POSITIONS:

1988 - 1997 Director, Psychosis Research Program
Department of Psychiatry
University of Pittsburgh
Pittsburgh, PA

1988 - 1992 Associate Professor of Psychiatry
Department of Psychiatry
University of Pittsburgh

	Pittsburgh, PA
1992 - 1997	Professor of Psychiatry Department of Psychiatry University of Pittsburgh Pittsburgh, PA
1994 – 1997	Professor of Psychology Department of Psychology University of Pittsburgh Pittsburgh, PA
1998 – 2005	Adjunct Professor of Psychiatry Department of Psychiatry University of Pittsburgh Pittsburgh, PA
2003-Present	Professor Department of Psychiatry and Behavioral Sciences SUNY, Downstate Medical Center Brooklyn, NY
2004-2014	Adjunct Professor and Senior Psychiatric Neuroscientist Department of Psychiatry Georgetown University School of Medicine Washington, DC

CERTIFICATION AND LICENSURE N/A:

MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

1969	American Psychological Association (Fellow)
1976	American College of Neuropsychopharmacology (Fellow)
1979	American Psychopathological Association (Fellow)
1982	Society for Clinical Trials
1984	Association for Clinical Psychosocial Research (Fellow)
1986	Society for Research in Psychopathology
1989	American Psychological Society (Fellow)
1997	Collegium Internationale Neuropsychopharmacologium (Fellow)
2004	International Society for CNS Clinical Trials and Methodology (Founding Fellow)

HONORS:

- 1951-1955 New York State Regents Scholarship
- 1953-1955 Tremaine Scholarship, CCNY
- 1955 Phi Beta Kappa
- 1991-1993 President, Association for Clinical Psychosocial Research
- 1994 Gralnick Foundation-High Point Hospital Award, presented by Education and Research Foundation of the National Association of Psychiatric Health Systems (joint with Samuel J. Keith, M.D.).
- 1997 American Psychological Foundation: Alexander Gralnick, M.D., Award
- 1998 National Alliance for Research on Schizophrenia and Depression: Distinguished Investigator Award
- 2000 President, American Psychopathological Association
- 2000 Samuel Hamilton Award, American Psychopathological Association
- 2001 Master in Psychiatry, Inova Health System
- 2002 Research Award, NAMI Queens Nassau
- 2003– 2010 Elected Councillor, Collegium Internationale Neuropsychopharmacologicum
- 2008 Hogarty Memorial Schizophrenia Research Award
- 2012 International Society for CNS Clinical Trials Methodology Distinguished Career Award
- 2015 American Society for Clinical Psychopharmacology Lifetime Achievement Award

PROFESSIONAL ACTIVITIES:

Teaching:

- 1988 - 1997 WPIC Residents. Schizophrenia Module. Tardive dyskinesia, diagnosis.
- 1988 - 1997 Psychiatric Epidemiology Seminars.
- 1989 - 1991 Mellon Summer Research Program Seminar.
- 1990 Clinical Services Research Training Program Seminar.
- 1990 Preceptor for Mellon Summer Research Program Fellow.
- 1990 Member, Dissertation Committee, Department of Psychology, Carnegie-Mellon University. Jonathan Cohen, M.D., "Attention and the Processing of Context: Parallel Distributed Processing Approach to Normal and Disordered Cognition."
- 1990 - 1992 Advanced Psychopharmacology Course for Fourth Year Residents. Western Psychiatric Institute and Clinic
- 1991 - 1992 Member, Masters Thesis Committee, Department of Psychology, University of Pittsburgh. Nancy Huxley, "Psychotic symptoms in relatives of schizophrenic patients."

- 1992 Member Dissertation Committee, Department of Education, University of Pittsburgh. Gemma Garrity Lundberg, M.S.N., "Risk of State Hospital Admission in Individuals with a Diagnosis of Schizophrenia."
- 1993 - 1995 Member Dissertation Committee, Department of Psychology, University of Pittsburgh. Judith Crowne, "Schizophrenia and frontal lobe development during young adulthood."
- 1994 - 1996 Member Dissertation Committee, Department of Psychology, University of Pittsburgh. Jennifer Brunke Stempel, "Social Functioning and Development of Liability for Schizophrenia: A Family Study."
- 1993 - 1996 Member Dissertation Committee, Department of Public Health, University of Pittsburgh. Marilyn Caveglia Kalish, "The Reaction to Dentistry Among Chronic Schizophrenic Individuals."
- 1995 - 1997 Member Dissertation Committee, Department of Psychology, University of Pittsburgh, Nancy Huxley, "Bizarre delusional ideation and frontal lobe functioning."
- 1996 - 1999 Primary Mentor, Sudha Pandalai, Ph.D. candidate in Epidemiology
- 1996 – 1999 Chair Dissertation Committee, Department of Epidemiology, University of Pittsburgh, Sudha Pandali, "The Relationship of Neurological, Psychopathology, Family, Psychosocial, Demographic, and History Factors to Relapse in the Maintenance Treatment of Schizophrenia."
- 1998 – 2003 Research Methodology for Second Year Residents Hillside Hospital
- 1998 – 2003 Treatment for Schizophrenia (PGY2) Hillside Hospital
- 2002 - Present Pharmacologic Treatment of Schizophrenia and Family Issues in Schizophrenia Psychology Interns, The Zucker Hillside Hospital
- 2003 – Present Lectures on Research /Clinical Integration All Residents SUNY Downstate
- 2004 – 2013 Course Director Schizophrenia didactic series PGY 2 Georgetown University School of Medicine
- 2004 – 2014 Lecturer, Schizophrenia Medical Students 2nd year, Georgetown University School of Medicine
- 2009 – Present Course Director, Research methodology, PGY2 SUNY Downstate Medical Center
- 2011 – Present Lecturer, Schizophrenia, Medical students 3rd year clerkship. SUNY Downstate Medical Center

Editorial:

- 1986 - Present Scientific Advisor, Journal of Clinical Psychiatry
- 1988 - Present Advisory Editor, Psychiatry
- 1989 - 1998 Associate Editor, Psychopharmacology Bulletin

1992 - 1999 Editorial Board, Experimental and Clinical Psychopharmacology
1996 – 2004 Editorial Board, Schizophrenia Bulletin
2008- Present Editorial Board, Clinical Schizophrenia & Related Psychoses

Reviewer for: academic Psychiatry, American Psychologist, Archives of General Psychiatry, American Journal of Psychiatry, Biological Psychiatry, Hospital and Community Psychiatry, Journal of Abnormal Psychology, Psychopharmacology, Journal of Clinical Psychopharmacology, The Journal of Neuropsychiatry and Clinical Neurosciences, Journal of Psychiatric Research, Psychiatry Research, Schizophrenia Research, Psychiatric Services. Neuropsychopharmacology, .European Neuropsychopharmacology

Organizational:

American College of Neuropsychopharmacology:

Program Committee 1979-1980; Publications Committee 1981-1983; Constitution and Rules Committee 1984-1986; Task Force to Revise Guidelines for Clinical Trials of Psychotropic Drugs 1989-1994; Task Force on Psychotropic Drug Prescribing Privileges for Nonphysicians 1989-1998; Co-Chair Committee on Education and Training 1993-1995; Member, Ad Hoc Committee to Examine Ethical Issues Involved in Controlled Clinical Trials 1994-1999; Member, Credentials Committee 2000-2002, Constitution and Rules Committee 2004 -2006, Relationship with Advocacy Groups 2006-2009, Ethics 2007 – 2010, Liaison between Government, Academia and Industry 2010 – 2013, Honorific Awards 2013 -2015...

Association for Clinical Psychosocial Research:

Council 1986-1996; Program Committee 1986-1989; Chair, Membership Committee 1989-1991; President 1991-1993

American Psychiatric Association:

Tardive Dyskinesia Task Force 1983-1989; Advisory Committee on Psychotic Disorders to the Work Group to Revise DSM-III 1984-1986; Advisor DSM-IV Schizophrenia Work Group 1989-1994

American Psychological Association:

Task Force for Revision of Guidelines for Psychologists for the use of Drugs in Research 1985; Prescription Privileges Officer, Psychopharmacology Division 1988-1990; Committee for Standards in Research 1990-1991, 1976-1987; Committee for Protection of Human Participants in Research

American Psychopathological Association:

Vice-President, President-elect, President, Past President 1998-2001.

International Society for CNS Clinical Trials Methodology

Science Committee 2006 – 2010, Co-Chair 2010 - 2012, Chair 2013 -2015, Finance Committee 2008 – 2010, Executive Committee 2007 – 2011, 2013 - 2015

Brain and Behavior Foundation = formerly the National Alliance for Research on Schizophrenia and Depression

Scientific Councillor 1986-Present; Member Review Committee for Young Investigator Awards 1988-present; Member Review Committee for Distinguished Investigator Awards 1988 - present, Member Review Committee for Independent Investigator Awards 1995 - Present, Chair Grant Follow-Up Committee 1990-present, Member Klerman Young Investigator Award Committee 1994 -Present.

National Alliance for the Mentally Ill
Member Scientific Council 2002 – 2010

Collegium Internationale Neuropsychopharmacologicum
Elected Councillor 2004 – 2010

Lundbeck International Neuroscience Foundation
Member, Faculty 2006 – 2013

Schizophrenia International Research Society
Member, Program and Awards Committees 2012-2014
Member, Publications Committee 2014-2016

RESEARCH:

Grants received:

Completed University of Pittsburgh

Federally funded:

4/89 - 3/93 MH45218 "Self Help and Severe Mental Illness."
Principal Investigator - Caroline Kaufmann, Ph.D.
Co-Investigator
National Institute of Mental Health

4/90 - 3/95 MH46614 "In Vivo ³¹p NMR Studies in Schizophrenics"
Principal Investigator - Jay Pettegrew, M.D.
Co-Investigator
National Institute of Mental Health.

4/90 - 12/97 MH45156 "Behavioral Neuroscience and Schizophrenia Research Center"
Principal Investigator - David Lewis, M.D.
Director: Clinical Services Core
National Institute of Mental Health.

4/92 - 3/95 MH46672 "Clozapine: Treatment Response and Disability."
Principal Investigator
National Institute of Mental Health.

4/95 - 12/97 MH46672 "New Antipsychotics: Clinical Trials and Naturalistic Followup"
Principal Investigator
National Institute of Mental Health.

Industry sponsored:

10/87-12/91 Protocol HPM "A Multi-center Double Blind Study Comparing Lower Doses of Haldol (Haloperidol Decanoate) Injection in the Maintenance Treatment of Patients with Schizophrenia."
Principal Investigator
McNeil Pharmaceutical Co.

11/89-10/92 Protocol 64,766/0204 "Risperidone in the Treatment of Chronic Schizophrenia, A Double Blind, Parallel Group Phase III Study."
Principal Investigator
Janssen Research Foundation.

11/89-10/92 Protocol 64,766/0205 "Risperidone in the Treatment of Chronic Schizophrenia, An Open Label, Group Extension Study."
Principal Investigator
Janssen Research Foundation.

8/91 - 6/94 Protocol 64766-0206 "The Long-Term Safety of Risperidone in the Treatment of Chronic Schizophrenia."
Principal Investigator
Janssen Research Foundation.

9/92 - 5/93 Protocol C90-835-04 "Safety, Tolerance and Pilot Efficacy of Rising Multiple Doses of SCH 39166 in Hospitalized Schizophrenic Patients: An Open Label Trial."
Principal Investigator
Schering-Plough Research Institute.

10/92 -10/93 Protocol M92-762 "A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Sertindole in Schizophrenic Patients."
Principal Investigator - Robert W. Baker, M.D.
Co-Principal Investigator
Abbott Laboratories - Neuroscience Venture.

10/92-10/94 Protocol M92-795 "An Open Label Assessment of the Long-Term Safety of Sertindole in the Treatment of Schizophrenic Patients."

Principal Investigator - Robert W. Baker, M.D.
Co-Principal Investigator
Abbott Laboratories - Neuroscience Venture.

5/94 - 5/95 Protocol M93-113 "A Double-Blind, Placebo-Controlled, Dose-Response Comparison of the Safety and Efficacy of Three Doses of Sertindole and Three Doses of Haldol7 in Schizophrenic Patients."
Principal Investigator - Robert W. Baker, M.D.
Co-Principal Investigator
Abbott Laboratories - Neuroscience Venture.

8/93 - 8/97 Protocol 16731D "Fixed-Dose Olanzapine Versus Placebo in the Treatment of Schizophrenia."
Principal Investigator
Lilly Research Laboratories.

1/95 - 12/97 Protocol 5077IL/0031:0009 "A Multicenter, Double-Blind, Randomized Comparison of ICI 204,636 Seroquel and Chlorpromazine in the Treatment of Hospitalized Subjects with Treatment-Resistant Schizophrenia and an Open-Label Extension Study"
Principal Investigator
Zeneca Pharmaceuticals.

1/95 - 7/97 Protocol M92-795 "An Open-Label Assessment of the Long-Term Safety of Sertindole in the Treatment of Schizophrenic Patients"
Principal Investigator
Abbott Laboratories.

3/97 - 12/97 Protocol RIS-INT-35 "Double-Blind Evaluation of Risperidone vs. Haloperidol on the Long-Term Morbidity of Early Psychotic Patients"
Principal Investigator
Janssen Pharmaceutica Research Foundation

Prior (at Long Island Jewish Medical Center):

Federally funded:

12/97-12/98 MH41960 Clinical Research Center for the Study of Schizophrenia
Director John M. Kane, M.D.
Associate Director

9/98 - 5/03 MH60004 Preventing Morbidity in First Episode Schizophrenia
Principal Investigator: John M. Kane, M.D.
Co-Principal Investigator

- 2/99 - 1/04 MH60575 Intervention Research Center: Course of Illness in Schizophrenia, Optimizing Outcomes
Director: John M. Kane, M.D.
Associate Director
- 7/99 - 6/04 MH60942 Longitudinal Neuro-imaging of First Episode Schizophrenia
Principal Investigator: Robert Bilder, Ph.D.
Co-investigator
- 9/99 - 8/04 MH60734 Clinical Trials in Schizophrenia: Molecular Approaches (Career Development Award)
Principal Investigator: Anil Malhotra
Primary Mentor
- 1/00 - 1/04 MH59784 Treatment of Negative Symptoms and Cognitive Impairments
Principal Investigator
- 9/02 – 8/03 MH64975 Stepped Pharmacotherapy for Aggressive Youth with ADHD (Career Development Award)
Principal Investigator: Joseph Blader
Primary Mentor
- 1/06-12/11 MH070023 Relapse Prevention Study: Steering and Implementation
The Zucker Hillside Hospital
Principal Investigator
1/06- 7/09 John M.Kane
7/09-12/11 NRS
Co-Principal Investigator 1/06-7/09

Industry sponsored:

- 7/99 - 1/00 Prospective randomized trial comparing iloperidone, risperidone and placebo in schizophrenia
Principal Investigator
Novartis Pharmaceuticals
- 11/99 - 7/00 Cross Titration of Ziprasidone with Olanzapine
Principal Investigator: John M. Kane, M.D.
Co-Principal Investigator
Pfizer Pharmaceuticals:

Foundation supported:

- 4/98 - 4/01 National Alliance for Research on Schizophrenia and Depression
Distinguished Investigator Award

A new rating scale to evaluate clinical change in schizophrenia
Principal Investigator

Completed at SUNY Downstate Medical Center

12/04 – 12/08 PREFER- Preventing First Episode Relapse
SUNY Downstate Medical Center
Ortho McNeil Janssen – Investigator Initiated Study
Principal Investigator Peter J. Weiden
Co-Principal Investigator

Current:

Federally funded

4/07- 9/12 MH077849-01A1 Interventions to test the alpha7 nicotinic receptor model in
schizophrenia
Georgetown University School of Medicine
Principal Investigator Stephen Deutsch
Co-Investigator

7/10 – 6/14 HHSN271200900019C
RAISE (Recovery After an Initial Schizophrenia Episode
SUNY Downstate Medical Center subcontract from
Feinstein Institute for Medical Research
Subcontract Principal Investigator

7/12 – 6/15 1C1CMS3331052-01-00
Health Care Innovation Challenge
Feinstein Institute for Medical Research
Project Director John M kane
Co-Investigator

Industry Funded

12/08 – present PREFER – Preventing First Episode Relapse
SUNY Downstate Medical Center
Ortho Mc Neil Janssen – Investigator Initiated study
Site Principal Investigator

Other Research Related Activities:

1976 - 1978 Acting Executive Secretary, Clinical Psychopharmacology Research Review
Committee, National Institute of Mental Health
1979 Reviewer of Tardive Dyskinesia Research proposals for State of Michigan
Department of Mental Health

- 1984 - 1997 Scientific Director, Treatment Strategies in Schizophrenia, Cooperative Agreement Program, National Institute of Mental Health
- 1985 - 1988 Coordinator, Pharmacologic and Somatic Treatments Research Consortium, National Institute of Mental Health
- 1985 - 1988 Chair, New Clinical Drug Evaluation Unit (NCDEU), Annual Meeting, National Institute of Mental Health
- 1986 - 1987 Chair, Schizophrenia Workgroup, Psychosocial Problems of Veterans, Veterans Administration
- 1986 - 1988 Co-Chair, Biologic and Psychosocial Treatments Panel, Schizophrenia National Plan, National Institute of Mental Health
- 1989 - 1990 Member, Special Grant Review Committee, National Institute on Drug Abuse
- 1989 - 1999 Member, Program Advisory Committee NCDEU Annual Meeting
- 1990 - 1994 Member, Psychopharmacologic Drugs Advisory Committee, Food and Drug Administration
- 1992 Member, Committee to review concept paper for ADHD, Cooperative Agreement Program, National Institute of Mental Health
- 1992 Member, International Committee for Relapse Prevention in Schizophrenia
- 1993-2000 Member, Research Advisory Panel, National Institute of Mental Health Clinical Research Center for Schizophrenia and Psychiatric Rehabilitation, University of California, Los Angeles (UCLA)
- 1993 - 1996 Member, Advisory Board, Patient Outcome Research Team (PORT) on Schizophrenia
- 1994 - 1997 Member, Research Advisory Panel, National Institute of Mental Health Clinical Research Center for Schizophrenia, Hillside Hospital - LIJ Medical Center, NY
- 1998 - 2000 Chair, Department of Veterans Affairs= Data Monitoring Board for CSP #451, "The Clinical and Economic Impact of Olanzapine in the Treatment of Schizophrenia"
- 1998 - 1999 Member, Behavioral Sciences Workgroup of the NIMH Advisory Council
- 1999- 2000 Member, Data Safety Monitoring Board, National Institute of Mental Health
- 2000- 2010 Chair, Data Safety Monitoring Board B. National Institute of Mental Health
- 2000-2001 Member, Veterans Administration Merit Review Board in Rehabilitation
- 2000 Member, Technical Evaluation Group "Follow-up of the Multimodal Treatment study of Children with Attention Deficit Hyperactivity Disorder" Contract Review, NIMH
- 2001-2005 Member, Scientific Advisory Board, Domenici Institute for Mental Illness/Neuroscience Discovery (MIND)
- 2001 Member, Special Grant Review Committee on Minority Training, National Institute of Mental Health
- 2002 Member, Special Grant Review Committee on Training, National Institute of Mental Health
- 2002 – 2008 Member Behavioral Genetics and Epidemiology Study Section, Center for Scientific Review, National Institutes of Health
- 2003-2008 Consultant, VISN 3 Mental Illness Research and Education Center
- 2006-2008 Consultant, Department of Psychiatry, Mt Sinai School of Medicine
- 2009 -2010 Co-Chair NCDEU 50th Anniversary Committee for 2010 meeting

2010- 2013 Co-Chair, NCDEU Meeting Steering Committee
2013- 2015 Member, NCDEU Meeting Steering Committee
2013 -2018 Member Collaborating Selection Committee, TRAM for Graham Boeckh
Foundation and Canadian Institute for Health Research (CIHR)
2014 Member, Special Grant Review Committee, National Institute of Mental Health

REPRESENTATIVE SEMINARS AND INVITED LECTURESHIPS - SINCE 1990:

Psychosocial and pharmacological treatment strategies in schizophrenia
Symposium: Current Trends in Intervention with Schizophrenia
22nd International Congress of Applied Psychology
Kyoto, Japan, July 1990

Multi Center Study of Fluphenazine Decanoate Dosage: Preliminary Stabilization Findings
Invited Speaker - 8th Alpenlandisches Psychiatrie Symposium
Innsbruck, Austria, September 1990

When the Hospital is Home
Workshop and video presentation at 7th Pennsylvania Schizophrenia Conference
Pittsburgh, Pennsylvania, March 1991

Psychosocial Rehabilitation of Schizophrenia
Grand Rounds, Lincoln Hospital
Bronx, NY, April 1991

Dose Effects in Relapsing Schizophrenic Patients
Symposium: Prediction of Relapse in Schizophrenia
American Psychiatric Association Meeting
New Orleans, LA, May 1991

Dose Reduction Strategies in Maintenance Treatment of Schizophrenia: An NCDEU Update
New Clinical Drug Evaluation Unit Annual Meeting
Key Biscayne, FL, May 1991

Alternate Drug Treatment Strategies for Maintenance in Schizophrenia: Review and Prognosis
Invited Speaker: Psychopharmacology of Schizophrenia
University of Calgary, July 1991

Maintenance Medication for Schizophrenia: Clinical Efficacy of Strategies for Dosage Reduction
Invited Speaker - International Congress on Schizophrenia & Affective Psychoses.
Geneva, Switzerland, September 1991

Assessment of Negative Symptoms and Drug-Induced Parkinsonism

Chair - Negative Symptoms Workshop
Hillside Hospital
Glen Oaks, NY, February 1992

Dosage Reduction Strategies in Maintenance Treatment of Schizophrenia
Invited Speaker - St. Francis Hospital & Medical Center
Hartford, CT, March 1992

Strategies for Long Term Treatment of Schizophrenia: The Interaction of Dose Reduction and Family Management
Grand Rounds - The Institute of Living and University of Connecticut Health Center
Hartford, CT, March 1992

Evaluating Antipsychotic Agents: New Clinical Trial Designs
Symposium: Novel Antipsychotic Agents: The Search for Safe and Effective First-Line Therapy
American Psychiatric Association Meeting
Washington, DC, May 1992

Discussant
Symposium: Neuroleptic Maintenance for Schizophrenia
American Psychiatric Association Meeting
Washington, DC, May 1992

Participant
Workshop: Personality Traits and Schizophrenia
American Psychiatric Association Meeting
Washington, DC, May 1992

Psychosocial Treatment of Schizophrenia: Role in the Acute Phases of the Illness
Invited Speaker - Guidelines for the Acute Treatment of Schizophrenia
Berlin, Germany, May 1992

Negative Symptoms as a Target of Medication Treatment: Definition and Assessment
Invited Speaker - Astra Workshop Zombie Effect
Stockholm, Sweden, September 1992

Long-term Treatment and Maintenance Strategies
Invited Speaker - Ninth Annual Pittsburgh Schizophrenia Conference
Pittsburgh, Pennsylvania, November 1992

Influence of Dose Reduction and Family Treatment on Longitudinal Course and Outcome
Symposium: Treatment Strategies in Schizophrenia: Effects of Dosage Reduction and Family Management on Patient Outcome, American College of Neuropsychopharmacology Annual Meeting,
San Juan, PR, December 1992

Preventing Schizophrenic Relapse: Dialogues in Depot Neuroleptic Therapy
KPR InforMedia Program

Invited Participant - Patient Management Using Depot Therapy
New York, NY, February 1993

Treatment Strategies in Schizophrenia: Effects of Dosage Reduction and Family Management on
Outcome

4th International Congress on Schizophrenia Research
Colorado Springs, CO, April 1993

Deficit symptoms in schizophrenia: Negative symptoms vs neuroleptic induced deficits

Symposium: Conventional neuroleptics and NIDS - an Overview

First International Meeting on Neuroleptic Induced Deficit Syndrome (NIDS)

Paris, France, May 1993

"Initial Findings: The Effects of Family Management and Dose Reduction"

Symposium: The NIMH Treatment Strategies in Schizophrenia Study: Assessing the Interaction of
Family Management and Dose Reduction

American Psychiatric Association Annual Meeting

San Francisco CA, May 1993

Reduced Dose and Family Management: Impact on Outcome

Symposium: Drug and Psychosocial Treatments in Schizophrenia

American Psychiatric Association Annual Meeting

San Francisco, CA, May 1993

The Role of Psychosocial Strategies

Symposium: Guidelines for Treatment of Acute Schizophrenia

American Psychiatric Association Annual Meeting

San Francisco, CA, May 1993

Rationale and Design of a Combined Trial in Maintenance Treatment of Schizophrenia

Symposium: Effects of Dosage Reduction and Family Management: The NIMH Treatment Strategies
in Schizophrenia Study

New Clinical Drug Evaluation Unit Annual Meeting

Boca Raton, FL, June 1993

A One-Year Comparison of Four Dosages of Haloperidol Decanoate (Poster)

New Clinical Drug Evaluation Unit Annual Meeting

Boca Raton, FL, June 1993

Quality of Life Issues in Maintenance Pharmacotherapy in Schizophrenia

Symposium: New Approaches to Psychiatric Treatment Assessment: Quality of Life

Ninth World Congress of Psychiatry

Rio de Janeiro, June 1993

Discussant

Symposium: New Approaches to Psychiatric Treatment Assessment: Quality of Life
Ninth World Congress of Psychiatry.
Rio de Janeiro, June 1993

Negative Symptom Change and Risperidone: Is There An Optimal Dose?
Satellite Symposium: Risperdal - New Horizons for the Schizophrenic Patient
Ninth World Congress of Psychiatry
Rio de Janeiro, June 1993

Targeted Medication in a Study of Dose Reduction and Family Management
Symposium: Intermittent Neuroleptic Treatment in Schizophrenia: State of the Art and Future
Development
Ninth World Congress of Psychiatry
Rio de Janeiro, June 1993

New Medications - Risperidone
Symposium: The New Atypical Antipsychotic Medications: What Can People Expect?
National Alliance for Mentally Ill Annual Convention
Miami Beach, FL, July 1993

New Medications for Schizophrenia: Therapeutic Impact and Side Effects
Symposium: Impact of Discoveries in Psychopharmacology on Clinical Psychology Practice
American Psychological Association Annual Meeting
Toronto, Ontario, Canada, August 1993

Pharmacologic and Psychosocial Maintenance Treatment Strategies for Schizophrenia
Grand Rounds L'Universite Laval
Quebec City, Quebec, Canada, September 1993

Relapse Prevention
Symposium: Innovations in Treating Psychoses
Hospital and Community Psychiatry Meeting
Baltimore, Maryland, October 1993

Treatment Strategies in Schizophrenia: Effects of Dosage Reduction and Family Management During
Maintenance Treatment
1993 Alden Memorial Lecture
Duke University Medical Center
Durham, North Carolina, October 1993

Treatment Strategies in Schizophrenia: Effects of Dosage Reduction and Family Management During
Maintenance Treatment
Grand Rounds - John Umstead Hospital

Duke University Medical Center
Durham, North Carolina, October 1993

The Outcome of Pharmacologic and Psychosocial Treatment Strategies
Symposium: Treatment Strategies in Schizophrenia
Emory University School of Medicine
Atlanta, Georgia, November 1993

Schizophrenia Treatment: Current Maintenance Strategies and Future Drug Development
Grand Rounds - University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, November 1993

Long-Term Treatment of Schizophrenia: Current State of the Field"
Symposium: New Approaches to Treating Schizophrenia
Theodore Van Putten Memorial Symposium
UCLA School of Medicine
Los Angeles, California, December 1993

Invited Speaker Contemporary Issues of Human Subject Protection
Special symposium: Informed Consent in Mental Health Research
Allegheny General Hospital
Pittsburgh, Pennsylvania, April, 1994

Treatment Strategies in Schizophrenia: Effects of Dosage Reduction and Family Management on
Patient Outcome
Symposium: Recent Developments in the Diagnosis and Treatment of Schizophrenia
Biella, Italy, May, 1994

Lo Studio del 'N.I.M.H.' Sulle Strategie di Trattamento nella Schizofrenia: Risultati ed Implicazioni
U.S.L. 27 - Bologna Ovest Servizio Salute Mentale
Bologna, Italy, May, 1994

Engaging Families in Treatment Affects Outcome
Symposium: Family Intervention Research Updated: Replicative and Comparative Outcome Studies
in Schizophrenia
American Psychiatric Association Annual Meeting
Philadelphia, Pennsylvania, May 1994

Can Psychosocial Treatment Enhance New Drug Efficacy?
Symposium: New Pharmacologic Approaches for Schizophrenia
American Psychiatric Association Annual Meeting
Philadelphia, Pennsylvania, May 1994

Maintenance Treatment: Drug and Psychosocial Effects
Symposium: "New Antipsychotic Treatments for Schizophrenia

1994 American Psychiatric Association Annual Meeting
Philadelphia, Pennsylvania, May 1994

Methodologic Issues in Clinical Trials Research
Symposium: "New Advances in Psychopharmacology"
2nd Annual Educational Program of the American Society of Clinical Psychopharmacology
Philadelphia, Pennsylvania, May 1994

Chair
Symposium: Who Enters Therapeutic Trials?
34th Annual Meeting of New Clinical Drug Evaluation Unit Program
Marco Island, FL, June 1994

Newer Antipsychotic Agents: Beyond Clozapine
Grand Rounds - Medical College of Pennsylvania, Eastern Pennsylvania Psychiatric Institute.
Philadelphia, PA, June 1994

Assessing the Negative Component of Psychosis: Rating Scales
Symposium: Negative and Affective Symptoms in Schizophrenia and Related Psychotic Disorders
XIXth C.I.N.P. Congress
Washington, DC, June 1994

What is the Value of Integrating Family Intervention Into Longterm Treatment of Schizophrenic Patients
Invited Speaker: 10th Alpenlandisches Psychiatrie Symposium
Innsbruck, Austria, September 1994

Measuring Outcomes for First Break Schizophrenia
Symposium: "Clinician's Measurement of Outcomes in Schizophrenia"
American Psychiatric Association Institute of Hospital & Community Psychiatry
San Diego, CA, October 1994

Integrating Family Psychoeducation into Treatment Programs of Schizophrenia
7th Annual New York State Office of Mental Health Research Conference
Albany, NY, December 1994

Combined Therapy for Optimal Maintenance Treatment of Schizophrenia
Grand Rounds - Belmont Center for Comprehensive Treatment
Philadelphia, PA, March 1995

Efficacy of Clozapine vs. Haloperidol in a Long Term Clinical Trial: Preliminary Findings
5th International Congress on Schizophrenia Research
Warm Springs, VA, April 1995

Family treatment of schizophrenia: when does it make a difference?

Symposium: Combining evidence on the efficacy of psychosocial treatment: meta analysis of available studies

Association for Clinical Psychosocial Research 12th Annual Meeting
Miami, FL, May 1995

Advances in maintenance treatment

Symposium: Advances in the Treatment of Schizophrenia
American Psychiatric Association Annual Meeting.
Miami, FL May 1995

Chair

Symposium: New and atypical anti-psychotic drugs
New Clinical Drug Evaluation Unit Program Annual Meeting
Orlando, FL, June 1995

Leader

Workshop: Making informed consent work
New Clinical Drug Evaluation Unit Program Annual Meeting
Orlando, FL, June 1995

Integration of family and drug treatment strategies

Symposium: Schizophrenia and How to Optimize the Pharmacological Therapy
Copenhagen, Denmark, June 1995

The treatment of schizophrenia and schizo-affective disorders

Symposium: Ask the Doctors
National Alliance for the Mentally Ill Annual Meeting
Washington, DC, July 1995

Medication compliance during long term treatment of schizophrenia

Consensus Conference: Clinical and Therapeutic Guidelines for Depot Neuroleptic Treatment in Schizophrenia
Siena, Italy, July 1995

Phenomenology of Schizophrenia

Invited Speaker: American Psychiatric Association CME
University of Syracuse
Syracuse, NY, September 1995

Family treatment for schizophrenia: When does it make a difference?

Symposium: Research on Behavioral Family Therapy for Psychiatric Disorders
Association for the Advancement of Behavior Therapy
Washington, DC, November 1995

Two year outcome of maintenance treatment: Effects of randomized medication assignment and rescue medication

Panel: Do Medication Free Periods Influence the Long Term Course in Schizophrenia
American College of Neuropsychopharmacology Annual Meeting
San Juan, Puerto Rico, December 1995

Long term efficacy of clozapine vs. haloperidol: A multi-center clinical trial
Satellite Meeting honoring Jonathan O. Cole, M.D.: Contemporary Clinical Psychopharmacology:
Relating Basic and Clinical Science
Organized and chaired meeting
American College of Neuropsychopharmacology Annual Meeting
San Juan, Puerto Rico, December 1995

Long Term Pharmacologic and Psychosocial Treatment
Symposium: Current Treatment of Schizophrenia
International Convention of Biological Psychiatry
Bombay, India, January 1996

Medications Under Development for Psychosis
Symposium: Newer Atypical Antipsychotic Agents
International Convention of Biological Psychiatry
Bombay, India, January 1996

Clozapine and Risperidone: Recent Findings
Symposium: Choosing Among Old and New Antipsychotics
American Psychiatric Association Annual Meeting
New York, NY, May 1996

Balancing Efficacy and Risk in Medication Choice
Symposium: Improving the Long-Term Course of Schizophrenia
American Psychiatric Association Annual Meeting
New York, NY, May 1996

Discussant
Symposium: New Approaches to Schizophrenia
American Psychiatric Association Annual Meeting
New York, NY, May 1996

The effect of medication free periods on long-term outcome
Grand Rounds, Department of Psychiatry
Oregon Health Sciences University
Portland, OR, September 1996

Integrating new medication into long-term care of schizophrenia
William G. Rondeau Lecture

Oregon Association for the Mentally Ill
Portland, OR, September 1996

Early intervention and course of illness
Symposium: Course of illness and outcome in schizophrenia
European College of Neuropsychopharmacology Annual Meeting Amsterdam, The Netherlands,
September 1996

Integrating psychosocial treatment approaches
Symposium: Schizophrenia: Biopsychosocial management and outcomes
American Psychiatric Association Institute on Psychiatric Services
Chicago, IL, October 1996

The Influence of Medication Free Periods on Long-Term Course in Schizophrenia
Invited Speaker - Guest Lecturer Program
University of Iowa Hospitals & Clinics
Iowa City, IA, November 1996

Clozapine and Risperidone: Recent Findings
Grand Rounds, Department of Psychiatry
University of Iowa Hospitals & Clinics
Iowa City, IA, November 1996

Long-Term Efficacy of Clozapine and Haloperidol for Treatment-Refractory Schizophrenics
Grand Rounds, Department of Psychiatry
Robert Wood Johnson Medical School
Piscataway, NJ, November 1996

Psychosocial Treatments of Schizophrenia: What Does Research Suggest?
Grand Rounds, Department of Psychiatry
Indiana University Medical Center
Indianapolis, IN, November 1996

Longitudinal Research in Schizophrenia
Grand Rounds, St. Francis Medical Center
Pittsburgh, PA, January 1997

Long-Term Treatments with New Antipsychotics
Symposium: From Temperament to Disease
II National Congress of the Italian Society of Psychopharmacology
Pisa, Italy, February 1997

Update on the Psychosocial Treatments of Psychosis
4th Annual Psychopharmacology Update
Ohio State University Medical Center
Columbus, OH, March 1997

Pharmacological Treatment of Early Psychosis
Conference on Early Psychosis Course
The University of Calgary
Calgary, Alberta, Canada, April 1997

First Improvement with Clozapine: How Patient Should We Be?
International Congress on Schizophrenia Research
Colorado Springs, Colorado, April 1997

What are the Critical Elements in Psychoeducation?
American Psychiatric Association Annual Meeting
San Diego, California, May 1997.

The Next Forty Years in Pharmacological Treatment - A Better Future for Patients with Schizophrenia?
Symposium: A Better Future for Patients with Schizophrenia - the Place of Risperidone
6th World Congress of Biological Psychiatry
Nice, France, June 1997

Decompensation after restitution in schizophrenia
Grand Rounds: University of California
Los Angeles, CA, May, 1998

Comparing new anti-psychotic medications: What do the data say?
President's Plenary Session - Frontiers of Antipsychotic Treatment
Annual Meeting of the Society of Biological Psychiatry
Toronto, Canada, May, 1998

A model for study of duration of untreated psychosis: Evidence from the Pittsburgh first episode study
Symposium: Duration of initially untreated psychosis: Impact in new studies of first episode schizophrenia
XXIst Collegium Internationale Neuropsychopharmacologium Congress
Glasgow, Scotland, July, 1998.

A basis for optimism - the implications of long-term treatment studies
Symposium: Pfizer satellite symposium
9th Congress of the Association of European Psychiatrists
Copenhagen, Denmark, September, 1998

Relationship of untreated psychosis to premorbid adjustment in schizophrenia
Grand Rounds, Department of Psychiatry
State University of New York at Stony Brook
Stony Brook, NY, October 1998

The pharmacological treatment of schizophrenia
Invited Plenary Speaker

3rd National Psychiatric Congress
Playa de Aro, Costa Brava, Spain, October, 1998

Long-term treatment of schizophrenia: Restabilization following relapse
Grand Rounds: Rush-Presbyterian-St. Lukes Medical Center
Chicago, IL, November, 1998
Meeting long term treatment goals: relapse prevention and more
Symposium: Optimizing wellness across the life cycle of schizophrenia
American Psychiatric Association
Washington DC, May 1999

Panel Chair, Toward Prevention in Schizophrenia
Second annual symposium
Search for Treatment in Early Psychosis (STEP)
Western Psychiatric Institute & Clinic
Pittsburgh PA, September 1999

Expectations for the Treatment of the First Episode
Symposium: Treating Schizophrenia from Clinical Trials to Clinical Practice
ECNP Contress
London, England, September 1999

The Research Base for Treatment of First Episode Schizophrenia
Symposium: Advances in the Treatment of Schizophrenia
Montefiore Medical Center
New York, NY, October 1999

Grand Rounds: Nassau County Medical Center
Treatment of First Episode Schizophrenia
Seminar Series in Psychiatry & Psychology
East Meadow, NY, December 1999

Chair: Study Group
New Methodological Issues in the Study of Treatment Refractory Schizophrenia
ACNP – 38th Annual Meeting
Acapulco, Mexico, December 1999

Grand Rounds: Schizophrenia – an update
Robert Wood Johnson Medical School
Piscataway, NJ, February 2000

Characteristics of First Episode Clinical Trial Subjects
2nd International Conference on early Psychosis – Future Possible
New York, NY, March 2000

Clozapine: Implications of Findings from Long Term Clinical Trials
Grand Rounds: Mount Sinai Medical Center
New York, NY, May 2000

Resocialization of schizophrenia. Effects of Medication and Psychosocial Treatment Strategies
Meeting of Hong Kong College of Psychiatrists
Hong Kong, China, July 2000

Long-term Treatment Goals: Clinical and Social Outcomes
Symposium: Optimizing Wellness in Schizophrenia for the Long Term
The Methodological Flaws and Advantages of Cross Comparison
Symposium: Comparing the Comparative Trials for Clinical Schizophrenia Practice
APA Institute on Psychiatric Services
Philadelphia, PA, October 2000

Life Cycle of Schizophrenia: Treatment Implications
Symposium: Advances in Treatment of Schizophrenia
Montefiore Medical Center
New York, NY, November 2000

Chair: Study Group
Early Detection of Schizophrenia: Clinical and Epidemiological Perspectives on Prevention
ACNP – 39th Annual Meeting
San Juan, PR, December 2000

Clozapine: Implications from Findings from Long-Term Clinical Trials
Grand Rounds: Queens Hospital Center
Jamaica, NY, January 2001

Presidential Address: Integration of Pharmacologic and Psychosocial Treatments: Long Term Outcome
Program Chair: Schizophrenia Lifetime Contributions to Research
American Psychopathological Association
New York, NY, March 2001

Schizophrenia: Scientific, Clinical and Economic Challenges to the VA
NAVAPAL/VA Conference
Ellicott City, MD, March 2001

Long-Term Outcome: Influence of Comorbid Conditions
Symposium: Management of Schizophrenia with Comorbid Disorders
Psychosocial Treatment for Schizophrenia
Symposium: Moving toward a more comprehensive management of patients with schizophrenia
2001 APA Annual Meeting
New Orleans, LA, May 2001

Psychosocial Treatments for Schizophrenia: Specific Strategies for Enhancing Treatment Response
First Episode of Schizophrenia: Treatment and Course
Psychopharmacology 2001 Congress
Capetown, South. Africa, September 2001

Evidence-based Psychosocial Treatment for Schizophrenia
Psychiatry Update: Care and Treatment of Schizophrenia
Washington University
St. Louis, MO, October 2001

Psychosocial Treatment of Schizophrenia: Newer Specific Approaches
Grand Rounds: University of Cincinnati
Cincinnati, OH, November 2001

Psychosocial Treatments for Schizophrenia: Newer Specific Approaches
Symposium: Advances in the Treatment of Schizophrenia
Montefiore Medical Center
New York, NY, November 2001

Focus on Long-term Management and Relapse Prevention
Symposium: Redefining Optimal Patient Management in Schizophrenia
14th annual U.S. Psychiatric & Mental Health Congress
Boston, MA, November 2001

Study Group: Remission and Demonstrating Efficacy in Clinical Trials
ACNP 40th Annual Meeting
Waikoloa, HI, December 2001

Psychosocial Treatments for Schizophrenia: Newer Specific Approaches
Grand Rounds – St. Vincent's Medical Center
New York, NY, December 2001

Focus on long term management and relapse prevention
American Psychiatric Association
Philadelphia, PA, May 2002

Program Cochairperson and Presenter
“Long-term outcome and comorbid conditions: Why do we know so little?”
Symposium: Management of Schizophrenia with Comorbid Conditions
Long-term Treatment Goals
Raising Expectations In Schizophrenia, Enhancing Long-Term Outcomes
15th Annual Meeting of American Psychiatric Association (APA)
Philadelphia, PA, May 2002

Maintenance Treatment in Schizophrenia
David Engelhardt Memorial Symposium
State University of New York, Downstate Medical Center
Brooklyn NY June 2002

Schizophrenia Treatment Goals: Long Term Control
Symposium Schizophrenia: Customizing Treatment Options
Institute on Psychiatric Services
Chicago IL October 2002

First Episode Treatment Studies
Annual Symposium Advances in the Treatment of Schizophrenia
Montefiore Medical Center
New York NY November 2002

Long Term Treatment; Long Term Perspectives
Visiting Professor
Grand Rounds
Department of Psychiatry, University of Pittsburgh School of Medicine
Pittsburgh PA , February 2003

Long Term Treatment of Schizophrenia
Grand Rounds
Jamaica Hospital
Queens NY April 2003

Outcomes in Behavioral RCTs: Linking Hypotheses and Outcome Assessments
NIH Staff Training Program in Clinical Trials
National Institutes of Health
Bethesda MD April 2003

Early Course of Schizophrenia: Implications of Treatment
Invited Lecture
NIMH Director's Round Table Meeting
Washington DC June 2003

Adherence: Revisiting Pharmacological and Psychosocial Interventions
Annual Symposium: Advances in the Treatment of Schizophrenia
Montefiore Medical Center
New York NY November 2003

First Episode Psychosis: Interventions and Outcomes
Grand Rounds
New Jersey Medical School
Newark NJ January 2004

Long term treatment: integrating pharmacological and psychosocial strategies
Speaker and Course Director
Advances in Schizophrenia Research: Targeting Clinical Applications
Georgetown University Hospital CME Course
Bethesda MD May 2004

Comprehensive management of schizophrenia:
Plenary Lecture
World Psychiatric Association Meeting
Florence, Italy November, 2004

Pharmacological and psychosocial interventions.
Colloquium
Department of Psychology, University of Maryland
College Park, Maryland, April 2005

Defining a path from relapse prevention to long term functional recovery
Symposium – Relapse Prevention in Schizophrenia
American Psychiatric Association Meeting
Atlanta, Georgia, May 2005

Glutamatergic therapy in schizophrenia: results of the CONSIST trial
Symposium
NCDEU Annual Meeting
Boca Raton Florida, June 2005

Group therapy for mental illness::route of administration or specific intervention
Symposium
Society for Clinical Trials
Orlando FL May 2006

A career in schizophrenia: from clinical trials to intervention research
New Investigator Workshop
NCDEU Annual Meeting
Boca Raton Florida, June 2006

Co-Chair Workshop
Measuring negative symptoms of schizophrenia: methodological hurdles to achieving an indication
NCDEU Annual Meeting
Boca Raton Florida June 2006

Measuring and monitoring patient outcomes: achieving positive results with negative symptoms
Symposium
European College of Neuropsychopharmacology

Paris France, September 2006

Course Director
Second Biennial Schizophrenia Conference
Novel and Emerging Strategies for Understanding and Treating Schizophrenia
Georgetown University Hospital
Washington DC, October 2006

The role of rating scales in clinical assessment of patients
Maryland Schizophrenia Conference
Baltimore, MD November, 2006

Integrating psychosocial and pharmacological treatments in schizophrenia
Pittsburgh Schizophrenia Conference
Pittsburgh PA, November 2006

Medication and medication strategies for first-episode schizophrenia
Grand Rounds
UCLA School of Medicine
Los Angeles, CA October 2007

Medication and medication strategies for “first episode schizophrenia
Plenary lecture
Institute for Psychiatric Services
New Orleans, LA October 2007

New dimensions in long-term schizophrenia treatment: efficacy in predominant negative symptoms
Symposium: New perspective in antipsychotic therapy
XXVI Collegium Internationale Neuropsychopharmacologicum Congress
Munich Germany July 2008

Negative symptoms in schizophrenia: identification, assessment and intervention
Symposium chair: Evolving priorities in antipsychotic therapy
European Congress of Neuropsychopharmacology
Barcelona Spain, September 2008

Medication and medication strategies for first episode schizophrenia
Momen Visiting Professor and Grand Rounds speaker
Medical College of Georgia
Augusta Georgia, September 2008

Schooler NR, Sunakawa A, Weiden PJ All-source verification: a new tool for measuring adherence in schizophrenia clinical trials
International Congress on Schizophrenia Research
San Diego CA April 2009

Abstract Schizophr Bull 2009; 35 (suppl 1) 366

Functional capacity and interview-based measures: RAND Panel judgments
In Symposium Evaluating Co-primary and Functional Measures for Clinical Trials of Cognition
Enhancers

International Congress on Schizophrenia Research
San Diego CA April 2009

Abstract Schizophr Bull 2009; 35 (suppl 1) 305

Functional outcome as a long-term treatment goal: definition and assessment in clinical trials
Schizophrenia International Research Society 2nd Biennial Meeting
Florence Italy April 2010

HDRS and BPRS: Characteristics that led to their success
Symposium co-chair: Instrumental Moments
NCDEU 50th Annual Meeting
Boca Raton FL June 2010

First episode schizophrenia: continuities and innovations in treatment
Grand Rounds Speaker
University of Vermont School of Medicine
Burlington Vermont September 2010

First episode schizophrenia: continuities and innovations in treatment
Grand Rounds Speaker
University of Texas Health Science Center San Antonio
San Antonio Texas, November 2010

Schooler NR, Weedon J, Sunakawa-McMillan A, Weiden PJ.
Long-acting injectable medication maintenance treatment of “first-episode” schizophrenia: a
randomized effectiveness study
International Congress on Schizophrenia Research
Boulder Colorado April 2011
Abstract *Schizophr Bull.* 2011; 37: (suppl 1) 320.

Schwartz BL Deutsch SI Schooler NR Rosse SM Brown CH Rosse RB
The effects of prolonged administration of an alpha7 nicotinic cholinergic agonist intervention on
neurocognitive function in schizophrenia
ACNP 2011 Annual meeting poster
Abstract *Neuropsychopharmacol* 2011

Schooler NR, Buckley PF, Mintz J, Goff DC, Kopelowicz A, Lauriello J, Manschreck TC, MendelowitzAJ,
Miller DD, Wilson D, Bustillo JR, Severe JB, Kane JM.
PROACTIVE: Initial Results of an RCT Comparing Long-acting Injectable Risperidone to 2nd Generation Oral

Antipsychotics
ACNP 2011 Annual meeting poster
Abstract *Neuropsychopharmacol* 2011 S104-105.

Deutsch SI Schooler NR Schwartz BL Brown CH Rosse SM Rosse RB An intervention to test the alpha7 nicotinic receptor model in schizophrenia: CDP-choline a cholinergic agonist and galantamine, a positive allosteric modulator
ACNP 2011 Annual meeting poster
Abstract *Neuropsychopharmacol* 2011

Schooler NR. The process of informed consent: the perspectives of a clinical investigator on the past and future
Ethics Plenary Session
“The Perils and Pitfalls of Biomedical Research: Historical and Contemporary Perspectives on the Ethics of Research.”
ACNP 2011 Annual Meeting, Waikiloa, Hawaii

First episode schizophrenia: continuities and innovations in treatment
Grand Rounds Speaker
SUNY Stony Brook
January 2012

First episode schizophrenia: continuities and innovations in treatment
Rachel Gundry Visiting Professor and Lecture
University of Maryland School of Medicine
February 2012

First episode schizophrenia: continuities and innovations in treatment
Grand Rounds Speaker
Georgetown University School of Medicine
February 2012

Schooler NR Symposium Chair
“Long-acting injectable antipsychotic medications: do recent studies change our understanding of their role in the treatment armamentarium?”
Presentation: PROACTIVE: Initial results of an RCT comparing long-acting injectable risperidone to 2nd generation oral antipsychotics
3rd Biennial Schizophrenia International Research Conference
Florence Italy
April 2012

Schooler NR RAISE-ETP Study: Rationale and Study Design
The Next Frontier in Mental Health: from Research to Patients Conference
Toronto Ontario, Canada
April 2012

Schooler NR Workshop Chair
Psychosocial Treatment Platforms in Psychopharmacology RCTs
NCDEU 52nd Annual Meeting
Scottsdale, Arizona
May 2012

“Treating the whole person in schizophrenia: medication adherence, pharmacologic and psychosocial treatments”

Brain and Behavior Research Foundation (formerly NARSAD) Women's Mental Health Conference: The Art and Science of Caring,
New York, New York
September, 2012.

Workshop Co-chair

Psychosocial treatment platforms in psychopharmacology RCTs: can they improve sensitivity in detecting medication differences

ISCTM Fall Meeting

Los Angeles CA

October, 2012

Plenary session Co-Chair

Statistical, Clinical, Payer and Regulatory Perspectives on Dimensions that Define the Spectrum of Efficacy/Explanatory and Effectiveness /Pragmatic Trials

ISCTM Fall Meeting

Los Angeles CA

October, 2012

Presentation (invited)

Are there changes in placebo response in schizophrenia clinical trials over time?

Symposium “The Decline Effect: Evidence, Explanations, and Future Directions”

UC-Santa Barbara CA

October 2012

Long-acting injectable antipsychotics for schizophrenia: evaluating information from clinical trials and naturalistic studies

Grand Rounds, Department of Psychiatry, Eastern Virginia Medical School, Norfolk VA

January 23, 2013

RAISE-ETP: an integrated model for treatment and study of first-episode psychosis in the US

Grand Rounds, Department of Psychiatry, University of Illinois- Chicago, Ill

April 9, 2013

Long-acting injectable antipsychotics: for schizophrenia: recent data and continuing questions

Theodore Van Putten Memorial Lecture

Westwood Veterans Affairs Medical Center, Los Angeles CA

May 2, 2013

The RAISE-ETP study design, research and implementation model

RAISE ETP Symposium
International Early Psychosis Association, Tokyo Japan
November 17, 2014

The RAISE-ETP study design, research and implementation model
RAISE-ETP Symposium
International Congress on Schizophrenia Research, Colorado Springs Colorado
March 30, 2015

Webinar: First Episode Psychosis: Characterization and Course
Brain and Behavior Research Foundation
April 14, 2014

Perspectives on Schizophrenia and Psychosis: pharmacologic treatment and course
Lifetime Achievement Award Presentation
American Society for Clinical Psychopharmacology, Miami Florida
June 23, 2015

Patient-reported medication and adherence to first episode psychosis guidelines in the RAISE-ETP RCT
In Symposium: Optimizing First Episode Psychosis Schizophrenia Medication Treatment by Community
Clinicians
American Society for Clinical Psychopharmacology, Miami Florida
June 23, 2015

Keynote Address: Introducing First Episode Psychosis
Lasting Hope Annual Conference: First Episode Psychosis, Omaha Nebraska
June 26, 2015

Nina Schooler
December 10, 2015

